About Seqirus New Zealand
CSL Group Websites
Seqirus New Zealand markets vaccines and pharmaceutical products in New Zealand with a focus on products for the prevention and treatment of serious disease.
We also in-license a number of products from partner companies to ensure a comprehensive range of products available to New Zealanders.History:
CSL companies have been represented in New Zealand since 1962 when CSL Bioplasma provided products to New Zealanders from New Zealand plasma. Since then CSL Behring Australia (formerly CSL Bioplasma and a part of CSL Biotherapies), has been the national plasma fractionators in New Zealand.
CSL Pharmaceuticals was set up in New Zealand in 1991 and changed it's name to CSL Biotherapies in 2006 in line with changes across the CSL Group. In January 2013, a reorganisation of the CSL Group saw a further name change to bioCSL (NZ) Ltd.
In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza vaccine company in the world.
Headquartered in Melbourne (Australia), the CSL Group includes CSL Ltd, Seqirus, CSL Behring and CSL Plasma. With major facilities in Australia, Germany, Switzerland, USA and Japan, CSL has over 11,000 employees worldwide.
Innovation and product development for unmet medical needs continue to drive bioCSL growth.